Polymyxin B sulfate clinical pharmacology
|Polymyxin B sulfate|
|NEOSPORIN® FDA Package Insert|
|Indications and Usage|
|Warnings and Precautions|
|Dosage and Administration|
|Labels and Packages|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. ; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. 
A wide range of antibacterial action is provided by the overlapping spectra of neomycin, polymyxin B sulfate, and gramicidin.
Neomycin is bactericidal for many gram-positive and gram-negative organisms. It is an aminoglycoside antibiotic which inhibits protein synthesis by binding with ribosomal RNA and causing misreading of the bacterial genetic code.
Polymyxin B is bactericidal for a variety of gram-negative organisms. It increases the permeability of the bacterial cell membrane by interacting with the phospholipid components of the membrane.
Gramicidin is bactericidal for a variety of gram-positive organisms. It increases the permeability of the bacterial cell membrane to inorganic cations by forming a network of channels through the normal lipid bilayer of the membrane.
Neomycin sulfate, polymyxin B sulfate, and gramicidin together are considered active against the following microorganisms: Staphylococcus aureus, streptococci, including Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. The product does not provide adequate coverage against Serratia marcescens.
- ↑ "NEOSPORIN (NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN) SOLUTION [MONARCH PHARMACEUTICALS, INC.]". Text " accessdate" ignored (help)
Adapted from the FDA Package Insert.